Biosign supplies monitoring gear to
TORONTO – Biosign Technologies Inc.
has announced the commercial launch of its UFIT system in the medical
research market. Under the terms of a purchase order from Algogene Pain
Genetics, Biosign will supply UFIT devices and online test, measurement
and analysis services to a study on chronic pain.
The study is a collaboration between The University of Toronto Centre
for the Study of Pain, The Centre for International Health, and Algogene
The collaboration is primarily aimed at identifying pain mechanisms and
genetic targets for developing better pain medication.
Biosign’s technology will be used to assess blood pressure, blood
glucose, autonomic nervous system features, and other parameters in
4,500 amputees over one year.
“In spite of a rigorous search, we were unable to find another
non-invasive measurement system that provides the kind of power and
versatility required for studying the interplay between morbidities such
as hypertension and diabetes associated with untreatable persistent
pain”, said Dr. Ze’ev Seltzer, the study’s lead investigator, a
professor of genetics at the Faculties of Dentistry and Medicine at the
University of Toronto, who holds a Canada Research Chair in Pain
About Biosign Technologies Inc.
Biosign provides technologies, products and initiatives to address
critical problems in global healthcare. The focus is on monitoring
health status, outcomes, and risk toward maximizing clinical awareness,
readiness, and effectiveness. The thrust is on enabling autonomous
medical care to optimize healthcare quality, access, and cost. The core
technology expands virtual instrumentation with universal measurement
and rapid knowledge formation to support service-oriented enterprising
across global markets. Trademarked UFIT, the web-based technology powers
several business lines in self-care, wellness, remote patient
monitoring, and chronic disease evaluation and management. Key
applications include intelligent systems for noninvasive monitoring of
common health risks such as high blood pressure, high blood glucose, and
adverse responses to medication. For more information on Biosign please
Posted Aug. 13/09.